文献速递肝病

未治疗慢性乙型肝炎患者肝硬化发病率的性别差异:一项10年中国队列研究

Sex Differences in Cirrhosis Incidence Among Untreated Chronic Hepatitis B Patients: A 10-year Chinese Cohort Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-06-10

该回顾性纵向队列纳入1543例未治疗慢性乙型肝炎患者(男760例,女774例),按2022年中国指南评估。男性肝硬化累积发病率显著高于女性(23.1% vs 7.9%),男性为肝硬化最强危险因素(HR 2.474)。结论提示可考虑扩大男性抗病毒治疗指征,而非女性。

要点

  • 未治疗CHB患者中男性肝硬化累积发病率23.1%,显著高于女性7.9%。
  • 男性是未治疗CHB患者肝硬化的最强危险因素(HR 2.474)。
  • 未达治疗标准的男性肝硬化发病率仍较高,而达标准的女性发病率较低。

核心结论

  • 未治疗慢性乙型肝炎患者中,男性肝硬化风险高于女性。
  • 可考虑扩大男性抗病毒治疗指征,而非女性;启动抗病毒治疗可按性别分层。

研究设计与样本

  • 回顾性纵向队列研究,纳入1543例未治疗慢性乙型肝炎患者(男760例,女774例)。
  • 患者均不符合既往指南抗病毒治疗标准,按2022年中国慢性乙型肝炎防治指南评估。

主要发现

  • 全部未治疗患者中,男性肝硬化累积发病率为23.1%,女性为7.9%(P < .001)。
  • 符合治疗标准患者中,男性肝硬化累积发病率为25.3%,女性为8.0%(P = .001)。
  • 不符合治疗标准患者中,男性肝硬化累积发病率为20.6%,女性为7.3%(P < .001)。
  • 未治疗患者中,男性是肝硬化最强危险因素(HR 2.474;95%CI 1.628-3.760;P < .001)。
  • 符合治疗标准的女性中,丙氨酸氨基转移酶异常者(10.4%)肝硬化发病率数值上高于正常者。

关键数值与推荐

  • 全部未治疗患者肝硬化累积发病率:男性23.1% vs 女性7.9%(P < .001)。
  • 符合治疗标准者肝硬化累积发病率:男性25.3% vs 女性8.0%(P = .001)。
  • 不符合治疗标准者肝硬化累积发病率:男性20.6% vs 女性7.3%(P < .001)。
  • 男性性别与肝硬化的风险比:HR 2.474(95%CI 1.628-3.760;P < .001)。

临床怎么用

  • 评估CHB患者抗病毒治疗指征时,可考虑将男性性别纳入风险分层。
  • 未达现行治疗标准的男性患者肝硬化风险仍较高,需加强监测。
  • 达治疗标准的女性患者肝硬化发病率相对较低,治疗决策可个体化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Current guidelines for antiviral treatment of chronic hepatitis B are based on age, alanine aminotransferase levels, viral load, a family history of hepatitis B virus-related cirrhosis, or hepatocellular carcinoma, while not considering sex as a factor. METHODS: This retrospective longitudinal cohort study included 1543 untreated patients with chronic hepatitis B (760 male and 774 female) not meeting antiviral treatment criteria in previous guidelines and investigated sex differences in liver disease progression according to the latest Chinese guidelines for the prevention and treatment of chronic hepatitis B (2022). RESULTS: The cumulative incidence of cirrhosis was significantly higher in male patients compared with female patients among all untreated patients with chronic hepatitis B (23.1% vs 7.9%; P < .001), treatment-eligible patients (25.3% vs 8.0%; P = .001), and treatment-ineligible patients (20.6% vs 7.3%; P < .001). Male sex was strongest risk factor for cirrhosis (hazard ratio, 2.474; 95% confidence interval, 1.628-3.760; P < .001) among untreated patients with chronic hepatitis B. Male patients showed a relatively high incidence of cirrhosis, although not meeting antiviral treatment criteria, whereas female patients showed a relatively low incidence of cirrhosis, although meeting antiviral treatment criteria. In treatment-eligible female patients, those with abnormal alanine aminotransaminase (10.4%) showed a numerically higher incidence of cirrhosis compared with those with normal alanine aminotransaminase. In treatment-ineligible patients, male sex was a risk factor for cirrhosis. CONCLUSIONS: In conclusion, male patients showed a higher risk of cirrhosis than female patients in untreated patients with chronic hepatitis B. Expanding antiviral treatment criteria may be considered in male patients, but not in female patients. Initiating antiviral treatment may be stratified by sex.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Tang Q, Zhou YH, Cai N, et al. Sex Differences in Cirrhosis Incidence Among Untreated Chronic Hepatitis B Patients: A 10-year Chinese Cohort Study. Clin Gastroenterol Hepatol. 2026. PMID: 42269997. doi:10.1016/j.cgh.2026.06.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。